Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topical EMLA pre-treatment fails to decrease the pain induced by 1% topical capsaicin.

Perry N Fuchs1, Marco Pappagallo, Richard A Meyer

  • 1Department of Neurosurgery, Johns Hopkins School of Medicine, 600 North Wolfe Street, Meyer 5-109, Baltimore, MD 21287 USA Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD USA Applied Physics Laboratory, The Johns Hopkins University, Johns Hopkins Road, Laurel, MD 20723, USA.

Pain
|May 26, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants.

International clinical psychopharmacology·2026
Same author

Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms.

Pharmacological research·2025
Same author

Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis: An Exploratory Post Hoc Analysis From a Phase 3 Randomized Controlled Trial.

The Journal of clinical psychiatry·2025
Same author

Reasons for Maintaining the Classification of Esmethadone as an Investigational Uncompetitive NMDAR Antagonist Rapid Antidepressant: Reply to Ferré and Michaelides.

The Journal of clinical psychiatry·2025
Same author

A Multidimensional Preclinical Investigation of the Biogenic Amine Depletion and Subchronic Swim Models of Fibromyalgia.

The journal of pain·2025
Same author

A novel artificial intelligence-based methodology to predict non-specific response to treatment.

Psychiatry research·2025
Same journal

Pain prevalence and intensity in advanced pancreatic cancer: a nationwide cohort study.

Pain·2026
Same journal

Neurobiology of the trigeminal ganglion in comparison to the dorsal root ganglion.

Pain·2026
Same journal

Peripheral kappa opioid receptors modulate cold hypersensitivity in a mouse model of chemotherapy-induced neuropathy.

Pain·2026
Same journal

Efficacy and effectiveness of melatonin for the management of musculoskeletal pain: a systematic review and meta-analysis of placebo and active controlled trials.

Pain·2026
Same journal

Predictive socio-cultural factors of pain intensity, disability, and quality of life in patients with nonspecific musculoskeletal pain: a prospective cohort study.

Pain·2026
Same journal

Reward-induced endogenous pain inhibition scales with action-outcome certainty in humans.

Pain·2026
See all related articles

EMLA (eutectic mixture of prilocaine and lidocaine) provided only short-term pain relief from topical capsaicin. It did not effectively block capsaicin-induced pain for neurogenic pain treatment.

Area of Science:

  • Pain Management
  • Dermatology
  • Pharmacology

Background:

  • Topical capsaicin is used for neurogenic pain but causes significant burning pain.
  • Patient adherence to topical capsaicin is limited by its adverse effects.

Purpose of the Study:

  • To evaluate if EMLA (eutectic mixture of prilocaine and lidocaine) can mitigate pain from topical capsaicin.
  • To assess EMLA's efficacy in blocking capsaicin-induced pain for improved patient tolerance.

Main Methods:

  • Nine healthy subjects received 1% topical capsaicin on forearms for 6 hours.
  • One arm was pretreated and cotreated with EMLA; the other received a vehicle control.
  • Pain ratings were recorded every 15 minutes on a 0-10 scale.

Main Results:

Related Experiment Videos

  • EMLA significantly reduced pain ratings only during the initial 15-30 minutes of capsaicin application.
  • No significant difference in pain ratings was observed between EMLA and vehicle sites after the initial period.
  • EMLA did not affect capsaicin-induced desensitization to heat stimuli.

Conclusions:

  • EMLA is ineffective for long-lasting attenuation of pain caused by topical capsaicin.
  • EMLA is not recommended for blocking capsaicin-induced pain in neurogenic pain management.